Valuation: PTC Therapeutics, Inc.

Market Cap 630.3Cr 546.75Cr 508.9Cr 467.58Cr 883.49Cr 60TCr 897.73Cr 6TCr 2.35TCr 30TCr 2.37TCr 2.32TCr 99TCr P/E 2026 *
67x
P/E 2027 * 30.1x
Enterprise Value 443.18Cr 384.44Cr 357.83Cr 328.77Cr 621.21Cr 42TCr 631.23Cr 4.22TCr 1.65TCr 21TCr 1.66TCr 1.63TCr 70TCr EV / Sales 2026 *
3.57x
EV / Sales 2027 * 3.59x
Free-Float
92.62%
Yield 2026 *
-
Yield 2027 * -
1 day-9.94%
1 week-13.31%
Current month-16.62%
1 month-16.62%
3 months+4.53%
6 months-9.96%
Current year-10.47%
1 week 64.57
Extreme 64.5675
79.33
1 month 64.57
Extreme 64.5675
90.87
Current year 61.43
Extreme 61.43
90.87
1 year 43.18
Extreme 43.175
90.87
3 years 17.53
Extreme 17.53
90.87
5 years 17.53
Extreme 17.53
90.87
10 years 4.03
Extreme 4.03
90.87
Manager TitleAgeSince
Chief Executive Officer 54 22/03/2023
Director of Finance/CFO 41 13/07/2023
Chief Tech/Sci/R&D Officer - 01/10/2017
Director TitleAgeSince
Chairman 74 01/11/2004
Chairman 80 31/03/1998
Director/Board Member 65 01/12/2005
Date Insider Type Main position Quantity % Market Cap.
14/07/26 Sell

Chief Financial Officer

-3,494 0.0042%
09/07/26 Fiscal year

Chief Technology Officer

7,392 0.0089%
09/07/26 Fiscal year

Director

47,502 0.0573%
Change 5-day change 1-year change 3-year change Capi.($)
-9.94%-13.31%+33.51%+66.16% 626.43Cr
-0.53%-3.12%+51.15%+150.58% 1,03000Cr
+0.21%-1.13%+53.26%+46.92% 62TCr
-2.51%-2.33%+32.56%+66.35% 45TCr
+0.06%+1.17%+36.21%+31.25% 35TCr
-0.14%-0.83%+33.24%+40.28% 30TCr
-0.69%-0.44%+9.86%+14.23% 27TCr
-7.37%-4.31%-5.69%-41.99% 23TCr
-0.64%+3.68%+27.80%+62.95% 21TCr
-0.82%-0.50%+13.46%+69.41% 16TCr
Average -2.13%+3.95%+28.54%+50.61% 36.19TCr
Weighted average by Cap. -0.85%+4.86%+36.60%+70.84%

Financials

2026 *2027 *
Net sales 124.05Cr 107.61Cr 100.16Cr 92Cr 173.88Cr 12TCr 176.68Cr 1.18TCr 463.18Cr 5.89TCr 465.84Cr 455.62Cr 20TCr 135.13Cr 117.22Cr 109.1Cr 100.24Cr 189.41Cr 13TCr 192.46Cr 1.29TCr 504.56Cr 6.42TCr 507.45Cr 496.31Cr 21TCr
Net income -2.27Cr -1.97Cr -1.83Cr -1.68Cr -3.18Cr -216.58Cr -3.23Cr -22Cr -8.48Cr -107.88Cr -8.53Cr -8.34Cr -357.41Cr 19Cr 17Cr 16Cr 14Cr 27Cr 1.84TCr 27Cr 183.72Cr 72Cr 917.12Cr 72Cr 71Cr 3.04TCr
Net Debt -187.11Cr -162.31Cr -151.07Cr -138.81Cr -262.27Cr -18TCr -266.5Cr -1.78TCr -698.65Cr -8.89TCr -702.66Cr -687.24Cr -29TCr -145.32Cr -126.06Cr -117.33Cr -107.8Cr -203.7Cr -14TCr -206.98Cr -1.38TCr -542.61Cr -6.9TCr -545.72Cr -533.75Cr -23TCr
Logo PTC Therapeutics, Inc.
PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).
Employees
991
Date Price Change Volume
31/26/31 $68.02 -9.93% 43,29,486
30/26/30 $75.52 +1.38% 13,74,880
29/26/29 $74.49 -1.19% 11,73,858
28/26/28 $75.39 -0.54% 14,87,692
27/26/27 $75.80 -1.33% 18,52,688
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
75.52USD
Average target price
96.93USD
Spread / Average Target
+28.35%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PTCT Stock